A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT07506863 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Transfusion-dependent Alpha-Thalassemia
Transfusion-dependent Beta-Thalassemia

Interventions

DRUG: Mitapivat Matched Placebo
DRUG: Mitapivat

Sponsor

Agios Pharmaceuticals, Inc.